CD163 and lobular neoplasia: Compared with those in SLE patients without LN, patients with other glomerular diseases, and healthy controls, the levels of urinary soluble CD163 in patients with active LN were shown to be significantly greater (Mejia-Vilet et al., 2020; Zhang et al., 2020), suggesting that urinary soluble CD163 may serve as a biomarker of LN.